INTRODUCTION
Cervical cancer screening recommendations currently are in flux as knowledge of human papillomavirus (HPV) and new, related technologies advance. Annual cervical cancer screening with Papanicolaou tests was recommended in the United States for many decades after its introduction. However, consideration of longer screening intervals gradually increased. In 2012, recommendations specifically advising against annual screening using any strategy were issued by the US Preventive Services Task Force 1 and separately by > 20 organizations coordinated by the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. Cytology alone at 3-year screening intervals or cotesting with HPV testing and cytology at 5-year intervals were both considered acceptable strategies for women aged 30 to 65 years. 2 The American College of Obstetricians and Gynecologists updated their guidelines shortly thereafter, and the guidelines became consistent with these other recommendations, although with a preference for 5-year cotests over 3-year Papanicolaou tests. 3, 4 These policy changes were based on strong evidence. Randomized controlled trials have consistently demonstrated that HPV testing is more sensitive than cytology for the detection of precancer (defined histologically as cervical intraepithelial neoplasia 3/adenocarcinoma in situ [CIN3/AIS]) and provides better reassurance against precancer and cancer, [5] [6] [7] [8] [9] which are important for extending screening intervals without placing women at greater risk. Large-scale observational data have shown even greater reassurance against cancer after cotesting compared with HPV testing alone, 10 although to our knowledge the gain appears to be quite small.
Assessment of the benefits and harms of different screening intervals remains subjective. Some experts do not accept the 5-year cotesting interval, and instead recommend repeated cotesting every 3 years to provide a greater reassurance against cervical cancer, while acknowledging the extra costs and procedures required when repeating a sensitive screening combination so frequently. 11 Nevertheless, many clinics continue to screen at even shorter intervals. However, to the best of our knowledge, the impact of screening at an interval that is shorter than recommended has not been sufficiently explored in a clinical setting. Theoretically, one might expect to note a decrease in screening efficiency and fewer precancers detected (compared with benign, newly appearing HPV infections and related minor cytologic changes) per screen over time.
Kaiser Permanente Northern California (KPNC), which is part of the Kaiser integrated health care system, has served as an important source of real-world evidence regarding 3-year cotesting since it began cotesting all eligible women aged 30 to 65 years at a 3-year interval starting in 2003. 12, 13 To obtain realistic clinical practice data, we examined the population-level effect on the detection of precancer and cancer after a decade-long experience with repeat 3-year screening intervals at KPNC.
MATERIALS AND METHODS

Study Population
The current analysis was based on the KP guidelines cohort, which includes all women enrolled at KPNC who have undergone cotesting since 2003, as previously described. 12, 13 As of the last data update through 2012, the cohort consists of nearly 1.5 million women, 2 million screening visits, and up to 10 years of follow-up per person. Consistent with KPNC screening protocols over the last decade, the current analysis was restricted to women aged 30 years, resulting in a study population of 1,065,273 women.
We defined 2 different cohorts. The "open cohort" referred to the group of women who were ever enrolled at KPNC and screened for cervical cancer between 2003 and 2012, the most recent year for which complete screening data were available for the current analysis. The open cohort represented the total yearly Kaiser experience. The "closed subcohort" included only the subset of women from the open cohort who were enrolled and received their first cotest in 2003 through 2004 (no women entering screening later were added to this group), and they were followed through 2012 as well. This group demonstrates the impact of repeated screening on a fixed population, and as such will be referred to as the "long-term screening cohort." Approximately 80% of women in this group had 2 cotests over the 10 years of follow-up, with only 10% having > 4 cotests.
We obtained all cytology and histology records for each of these women starting from their first visit (in 2003 or later) through their last visit or the end of 2012, whichever occurred earlier. Because we did not have an indicator of whether a woman underwent a colposcopy, we used the presence of a biopsy result as a marker that a colposcopy was performed.
Statistical Analysis
Descriptive statistics of the 2 cohorts were compared, including numbers of screening visits and screening results. Because the results first were assessed by year on a population and not individual level, we did not calculate true rates, but rather ratios of the outcome detected (ie, CIN3/AIS or cancer) to the number of cotests and colposcopic visits performed. We first calculated the ratios of precancer/cancer diagnosis to the number of cotests performed for all women who received cervical cancer screening from age 30 years onward at KPNC from 2003 to 2012 (the open cohort). To estimate the cumulative impact of repeated screening at 3-year intervals, we calculated that same ratios for the long-term screening cohort. We smoothed the trend data by taking the average of 3 years in the early, middle, and late parts of the decade (2004-2006, 2007-2009, and 2010-2012) . Statistical significance was determined using trend tests. The number of colposcopies performed (herein limited to those resulting in a biopsy) compared with the number of screening tests and outcomes per colposcopy-biopsy visit were similarly compared. All rates in Tables 1 to 3 were age-adjusted using the 2000 US Census population as the reference.
RESULTS
Population characteristics of both cohorts at the time of the enrollment visit are shown in Table 1 . Women in the long-term screening cohort, who underwent their first cotest at KPNC in 2003 to 2004 when cotesting was introduced, were on average aged 2 years older than women in the open cohort and had lower high-risk HPV prevalence at baseline using Hybrid Capture 2 (Qiagen,
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Germantown, Md) (5.1% vs 5.9%; P<.001). They also had a lower prevalence of abnormal cytology (atypical squamous cells of undetermined significance or worse) (3.8% vs 4.6%; P<.001).
In the open cohort, the ratio of colposcopic biopsy visits to cotests performed nearly doubled from 1373.5 per 100,000 women screened to 2738.4 per 100,000 women screened (Table 2) , and the rate of histologically diagnosed precancer (CIN3/AIS) per cotest increased from the first period to the second (82.0/100,000 women screened to 140.6/100,000 women screened; P 5 .001), and then had a small decrease in the third period (140.6/ 100,000 women screened to 126.0/100,000 women screened; P<.001). The increase in the relative number of biopsies taken combined with the increase in CIN3/AIS detection resulted in a stable number of biopsy visits needed to detect a case of CIN3/AIS (between 16 and 22 visits) in the open cohort over the study period.
In the long-term screening cohort, which was the population of women who were enrolled in 2003 to 2004 (many of whom continued to be cotested regularly. with a median screening interval of 2.9 years [interquartile range, 2.1-3.2 years]), the number of biopsy visits relative to cotests increased by 80% (Table 2) . When examining the 3-year averages in the long-term screening cohort, there was a significant increase in the rate of CIN3/AIS detected per 6/100,000 women screened to 5.4/100,000 women screened); however, this was followed by a reduction of nearly equal magnitude, resulting in rates for 2010 to 2012 that were similar to those at baseline (4.2/100,000 women screened). In the long-term screening cohort, no change was noted in the detection of adenocarcinoma over the 3 time periods (remaining between 4 to 5/100,000 women screened). The open cohort demonstrated a decrease in the detection of squamous cell carcinoma from the first to the second time period (13.1/100,000 women screened to 10.1/ 100,000 women screened), but this was followed by an increase in the latest time period to 14.9 per 100,000 women screened. The long-term screening cohort demonstrated a much larger decrease in the detection of squamous cell carcinoma from 13.0 per 100,000 women screened to 4.6 per 100,000 women screened in 2007 to 2009, at which it remained in the latest period, resulting in a reduction from the early to late 3-year period of 65%.
DISCUSSION
An ideal cervical screening interval is characterized by the detection of a useful number of treatable precancers and extremely few invasive cancers. Too frequent screening will produce many newly appearing HPV infections and lowgrade abnormalities but few true precancers at each screening round, thereby increasing the potential for overtreatment. Conversely, too infrequent screening may allow for the development of an unacceptably large number of invasive cancers. Because current guidelines suggest that a 3-year cotest interval is too frequent, we expected to observe an overall decrease in screening efficiency with time across the system. Instead, we found that the every-3-year cotesting strategy used by KPNC, judged as an open cohort with a continuing influx of women at risk, yielded an increasing rate of precancers per woman screened, but an unchanged, low rate of adenocarcinomas and invasive squamous cell cancers. This suggests that the program largely is achieving what screening is designed to do, namely detect precancers, although little corresponding decrease is observed in cancer rates. However, the cost is still a high referral rate to colposcopy.
The long-term screening cohort represented the accumulated experience of women receiving longitudinal, repeated 3-year cotesting. In this group, the relative detection of precancer to screening tests remained relatively steady, whereas the ratio of cancer found per screening test was unchanged for adenocarcinoma but decreased by nearly 67% for squamous cell carcinoma. It is in this group with repeated cotests that a decrease in screening efficiency becomes evident, particularly after the second round of screening, at which time an almost doubling in the number of colposcopic biopsies needed for the detection of a single precancerous lesion is observed.
Comparing the open cohort with the long-term screening cohort, there was no decrease in the detection of precancer noted in the open cohort, but rather a steady increase. The increase in the open cohort most likely is due to a combination of women aging into screening eligibility and a change in repeatedly referring HPV-positive women to colposcopy, as well as new enrollees into KPNC. These newly cotested women likely brought along a continued influx of disease that could then be detected by screening. Comparing these cohorts provides 2 different but equally valid descriptions of the clinical practice outcomes that are occurring simultaneously: the open cohort provides a snapshot of what is occurring at KPNC on a routine basis with the in-migration of new patients, whereas the long-term Original Article screening cohort illustrates a screening program perspective, one in which women are not just screened once but rather repeatedly over a lifetime, both of which are necessary to consider when evaluating the impact of screening. Over the past 10 years, the open cohort and longterm screening cohort yielded a somewhat comparable percentage of cancers per colposcopy performed, but the long-term screening cohort yielded fewer cases of CIN3/ AIS per colposcopy compared with the open cohort. Increased biopsy visits with the detection of fewer precancers among the regularly cotested women in the closed cohort may suggest some loss in screening efficiency.
We initiated the current analysis with a prior hypothesis that cotesting at repeat 3-year intervals would lead to some degree of inefficiency and overmanagement. The results proved more complicated than we expected. Changes over time in screening program policies, in particular who is referred to colposcopy, might have influenced the ratios and introduced bias in the time trends. Moreover, the current analysis was conducted on a population level, not the individual level. Given the importance of the issues and the ambiguous secular trends, we will conduct a women-level longitudinal analysis of cumulative incidence rates to assess better the cumulative effect of long-term cotesting at 3-year intervals. Because many clinics have yet to attain a 3-year screening interval, data demonstrating the impact of this interval may prove important in encouraging the shift to a 3-year model, which is likely a necessary step on the way toward the recommended 5-year interval.
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